


An Open-label, Multicenter, Phase 2 Study of Sacituzumab Govitecan Combinations in First-line Treatment of Patients with Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC) Without Actionable Genomic Alterations

Study Design

Trial registration number: NCT05186974



Enrollment and key eligibility criteria

Key Inclusion Criteria:

- Pathologically documented stage IV NSCLC
- No prior systemic treatment for mNSCLC
- ECOG performance status score of 0 or 1
- Has no known genomic alterations in actionable driver oncogenes with approved therapies for frontline treatments
- Adequate renal and hepatic function as well as hematologic counts

Key Exclusion Criteria:

- Mixed SCLC and NSCLC histology
- Active secondary malignancy
- Have previously received treatment with Topoisomerase 1 inhibitors, Trop-2 targeted therapy
- Active CNS metastases or carcinomatous meningitis
- Currently participating in a clinical trial

Questions?

- For more information on this study, please contact GileadClinicalTrials@gilead.com

Safety and efficacy have not been demonstrated for the investigational uses described here. There is no guarantee that the investigational therapies or uses will be approved for use. Visit clinicaltrials.gov for more information. Clinicaltrials.gov: NCT#05186974

AUC, area under the concentration versus time curve; CNS, central nervous system; DCR, disease control rate; DOR, duration of response; ECOG, Eastern Cooperative Oncology Group; IRC, independent review committee; IV, intravenous; m, metastatic; NSCLC, non-small cell lung cancer; nsq, nonsquamous histology; ORR, objective response rate; OS, overall survival; PFS, progression-free survival; PD-L1, programmed cell death ligand 1; RECIST, Response Evaluation Criteria in Solid Tumors, version 1.1; RP2D, recommended Phase 2 dose; SCLC, small-cell lung cancer; sq, squamous histology; TPS, tumor proportion score.

References:

National Institutes of Health. <https://clinicaltrials.gov/ct2/show/NCT05186974>. Accessed January 18, 2022.
Gilead Sciences Data on File.

GILEAD ONCOLOGY and the GILEAD ONCOLOGY logo are trademarks of Gilead Sciences, Inc., or its related companies.
© 2022 Gilead Sciences, Inc. All rights reserved. US-UNBP-0592 2/22



Oncology